fmicb.2015.01405

u-Plasminogen Activator/Urokinase Antibody Summary

    Immunogen
    Native human uPA.
    Specificity
    Recognizes human uPA alone and also as a complex under reducing and native conditions.
    Isotype
    IgG
    Clonality
    Polyclonal
    Host
    Sheep
    Gene
    PLAU
    Purity
    Protein G purified
    Innovators Reward
    Test in a species/application not listed above to receive a full credit towards a future purchase.

    Learn about the Innovators Reward

Applications/Dilutions

    Dilutions
        Western Blot 1-5 ug/ml
        ELISA 1:100000
    Positive Control u-Plasminogen Activator/Urokinase Lysate (NBL1-14486)

Reactivity Notes

Cross reacts with Human.

Packaging, Storage & Formulations

    Storage
    Store at -80C. Avoid freeze-thaw cycles.
    Buffer
    50mM Sodium Phosphate (pH 6.6), 0.1M NaCl and 1mM EDTA
    Preservative
    No Preservative
    Concentration
    1.0 mg/ml
    Purity
    Protein G purified

Alternate Names for u-Plasminogen Activator/Urokinase Antibody

      ATF
      EC 3.4.21
      EC 3.4.21.73
      plasminogen activator, urokinase
      PLAU
      uPA
      u-PA
      uPlasminogen Activator
      u-Plasminogen Activator
      urinary
      Urokinase
      urokinase-type plasminogen activator

Background

Urokinase is a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in the Urokinase gene may be associated with late onset Alzheimer disease and also with decreased affinity for fibrin binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg Val bond in plasminogen. The proprotein is cleaved at a Lys Ile bond by plasmin to form a two chain derivative in which a single disulfide bond connects the amino terminal A chain to the catalytically active, carboxy terminal B chain. This two chain derivative is also called HMW uPA (high molecular weight uPA). HMW uPA can be further processed into LMW uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino terminal fragment. LMW uPA is proteolytically active but does not bind to the uPA receptor.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

RG109

Related Post